| 1 |
35158894 | Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas. | 2022 Jan 26 |
1 |
| 2 |
34204102 | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. | 2021 Jun 6 |
1 |
| 3 |
34227176 | Ibritumomab Tiuxetan Radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma. | 2021 Nov |
1 |
| 4 |
27497027 | Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned? | 2016 Sep |
1 |
| 5 |
25677780 | Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant. | 2015 |
1 |
| 6 |
25379535 | Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. | 2014 |
1 |
| 7 |
25440606 | Radioimmunoconjugates for the treatment of cancer. | 2014 Oct |
1 |
| 8 |
25596049 | [Cancer therapy using unsealed radioisotopes-the present and future]. | 2014 Dec |
1 |
| 9 |
23875170 | Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma. | 2013 |
1 |
| 10 |
21571787 | 90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma. | 2011 Jun |
1 |
| 11 |
21575926 | (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. | 2011 Apr |
1 |
| 12 |
21034409 | Current concepts and future directions in radioimmunotherapy. | 2010 Dec |
1 |
| 13 |
18773247 | Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma. | 2009 Jan-Feb |
1 |
| 14 |
19427037 | Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. | 2009 Jul |
2 |
| 15 |
19642457 | [Monoclonal antibodies in hematology in 2009]. | 2009 May-Jun |
1 |
| 16 |
19819920 | Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. | 2009 |
1 |
| 17 |
18194857 | Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. | 2008 Feb |
1 |
| 18 |
18268399 | Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. | 2008 Feb |
2 |
| 19 |
18927323 | 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging. | 2008 Nov |
1 |
| 20 |
19061730 | [Contribution of radioimmunotherapy to the treatment of lymphoma]. | 2008 Nov-Dec |
1 |
| 21 |
17287964 | [Therapy of follicular lymphoma]. | 2007 Apr |
1 |
| 22 |
17323056 | EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). | 2007 Apr |
1 |
| 23 |
17396483 | Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. | 2007 Feb |
1 |
| 24 |
17886241 | Yttrium 90 ibritumomab tiuxetan (Zevalin): a new bullet in the fight against malignant lymphoma? | 2007 Nov |
1 |
| 25 |
16321828 | Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. | 2006 Jan |
1 |
| 26 |
16540013 | [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status]. | 2006 Jan-Feb |
1 |
| 27 |
16826593 | Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. | 2006 Aug 15 |
1 |
| 28 |
16979437 | Logistics of therapy with the ibritumomab tiuxetan regimen. | 2006 |
1 |
| 29 |
16979439 | Radioimmunotherapy in a radiation oncology environment: building a multi-specialty team. | 2006 |
1 |
| 30 |
17087138 | [90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab]. | 2006 Jul-Aug |
1 |
| 31 |
15786024 | Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. | 2005 Feb |
1 |
| 32 |
15786026 | Development of 131I-tositumomab. | 2005 Feb |
1 |
| 33 |
15802280 | Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. | 2005 May |
1 |
| 34 |
16091197 | New developments in immunotherapy for non-Hodgkin's lymphoma. | 2005 Sep |
1 |
| 35 |
16111589 | Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. | 2005 Sep 1 |
1 |
| 36 |
16203814 | Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. | 2005 Oct 1 |
1 |
| 37 |
16304400 | Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. | 2005 |
1 |
| 38 |
15016644 | Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. | 2004 Jun 15 |
2 |
| 39 |
15023434 | Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues. | 2004 Apr |
1 |
| 40 |
15045033 | Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. | 2004 Feb |
2 |
| 41 |
15342663 | Clinical trials for malignant lymphoma in Japan. | 2004 Jul |
1 |
| 42 |
15498146 | Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. | 2004 Oct |
1 |
| 43 |
15844660 | Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin). | 2004 Dec |
1 |
| 44 |
20641770 | Single-walled carbon nanotubes-111In-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-rituximab | 2004 |
1 |
| 45 |
12621016 | Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. | 2003 Mar |
2 |
| 46 |
12663713 | Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. | 2003 Apr 1 |
1 |
| 47 |
12837157 | Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. | 2003 Jun |
3 |
| 48 |
14529425 | Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. | 2003 Aug |
1 |
| 49 |
15154741 | Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. | 2003 |
1 |
| 50 |
15154742 | Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy. | 2003 |
2 |